Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment

被引：205
|
作者：
Oeckl, Patrick [1 ]
Halbgebauer, Steffen [1 ]
Anderl-Straub, Sarah [1 ]
Steinacker, Petra [1 ]
Huss, Andre M. [1 ]
Neugebauer, Hermann [1 ]
von Arnim, Christine A. F. [1 ]
Diehl-Schmid, Janine [2 ]
Grimmer, Timo [2 ]
Kornhuber, Johannes [3 ,4 ]
Lewczuk, Piotr [3 ,4 ,5 ]
Danek, Adrian [6 ]
Ludolph, Albert C. [1 ]
Otto, Markus [1 ]
机构：
[1] Ulm Univ Hosp, Dept Neurol, Oberer Eselsberg 45, D-89081 Ulm, Germany
[2] Tech Univ Munich, Dept Psychiat & Psychotherapy, Klinikum Rechts Isar, Munich, Germany
[3] Univ Klinikum Erlangen, Dept Psychiat & Psychotherapy, Erlangen, Germany
[4] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen, Germany
[5] Med Univ Bialystok, Dept Neurodegenerat Diagnost, Bialystok, Poland
[6] Ludwig Maximilians Univ Munchen, Dept Neurol, Univ Hosp, Munich, Germany
[7] Univ Ulm, German Consortium Frontotemporal Lobar Degenerat, Ulm, Germany
来源：
JOURNAL OF ALZHEIMERS DISEASE | 2019年 / 67卷 / 02期
关键词：
Alzheimer's disease; astrocyte; biomarker; cerebrospinal fluid; differential diagnosis; frontotemporal dementia; GFAP; Lewy body dementia; Parkinson's disease; serum; NEUROFILAMENT LIGHT-CHAIN; CEREBROSPINAL-FLUID; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; PLASMA; DEMENTIA; RECOMMENDATIONS; CRITERIA; LEVEL;
D O I：
10.3233/JAD-180325
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r = -0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.
引用
收藏
页码：481 / 488
页数：8
相关论文
共 50 条
  • [1] Subcortical tau deposition and plasma glial fibrillary acidic protein as predictors of cognitive decline in mild cognitive impairment and Alzheimer's disease
    Chang, Yan
    Liu, Jiajin
    Xu, Xiaodan
    Sun, Shuwei
    Zhang, Jinming
    Zhang, Xiaojun
    Lu, Guangshuang
    Xiao, Shaobo
    Cao, Yuanyan
    Wu, Runze
    Wu, Jun
    Liu, Ruozhuo
    Wang, Ruimin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025, 52 (04) : 1496 - 1509
  • [2] Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity
    Hogel, Heidi
    Rissanen, Eero
    Barro, Christian
    Matilainen, Markus
    Nylund, Marjo
    Kuhle, Jens
    Airas, Laura
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (02) : 210 - 219
  • [3] Glial fibrillary acidic protein in Alzheimer's disease: a narrative review
    Leipp, Florine
    Vialaret, Jerome
    Mohaupt, Pablo
    Coppens, Salome
    Jaffuel, Aurore
    Niehoff, Ann-Christin
    Lehmann, Sylvain
    Hirtz, Christophe
    BRAIN COMMUNICATIONS, 2024, 6 (06)
  • [4] Evaluation of serum neurofilament light chain and glial fibrillary acidic protein in the diagnosis of Alzheimer's disease
    Fang, Tangni
    Dai, Yaqian
    Hu, Xueyi
    Xu, Yuanhong
    Qiao, Jinping
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [5] Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease
    Yang, Zhengshi
    Sreenivasan, Karthik
    Strom, Erin N. Toledano
    Osse, Amanda M. Leisgang
    Pasia, Lorenzo Gabriel
    Cosme, Celica Glenn
    Mugosa, Maya Rae N.
    Chevalier, Emma Lea
    Ritter, Aaron
    Miller, Justin B.
    Cordes, Dietmar
    Cummings, Jeffrey L.
    Kinney, Jefferson W.
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [6] Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease
    Zhengshi Yang
    Karthik Sreenivasan
    Erin N. Toledano Strom
    Amanda M. Leisgang Osse
    Lorenzo Gabriel Pasia
    Celica Glenn Cosme
    Maya Rae N. Mugosa
    Emma Léa Chevalier
    Aaron Ritter
    Justin B. Miller
    Dietmar Cordes
    Jeffrey L. Cummings
    Jefferson W. Kinney
    Alzheimer's Research & Therapy, 15
  • [7] Serum Levels of Glial Fibrillary Acidic Protein Association with Cognitive Impairment and Type 2 Diabetes
    Ayala-Guerrero, Lorelei
    Garcia-delaTorre, Paola
    Sanchez-Garcia, Sergio
    Guzman-Ramos, Kioko
    ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (05) : 501 - 507
  • [8] Quantification of regional glial fibrillary acidic protein levels in Alzheimer's disease
    Ross, GW
    O'Callaghan, JP
    Sharp, DS
    Petrovitch, H
    Miller, DB
    Abbott, RD
    Nelson, J
    Launer, LJ
    Foley, DJ
    Burchfiel, CM
    Hardman, J
    White, LR
    ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 (05): : 318 - 323
  • [9] Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease brain
    Korolainen, MA
    Auriola, S
    Nyman, T
    Alafuzoff, H
    Pirttilä, T
    NEUROBIOLOGY OF AGING, 2004, 25 : S536 - S537
  • [10] Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer's Disease
    Ganne, Akshatha
    Balasubramaniam, Meenakshisundaram
    Griffin, W. Sue T.
    Reis, Robert J. Shmookler
    Ayyadevara, Srinivas
    PHARMACEUTICS, 2022, 14 (07)
12345